The Medical Letter on Drugs and Therapeutics
Citalopram (Celexa) and QT Interval Prolongation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has asked the manufacturers of the selective serotonin reuptake inhibitor (SSRI) antidepressant citalopram (Celexa, and others) to revise the labeling of the drug to include new warnings about the risk of QT interval prolongation.1

THE DATA — The FDA based its warnings on postmarketing reports of QT interval prolongation and the potentially fatal torsades de pointes cardiac arrhythmia in patients taking citalopram (number of patients and clinical details not specified) and on data from an unpublished study in 119 healthy non-depressed volunteers, which found that the change in corrected QT interval [QTc] was 8.5 msec with 20 mg/d of citalopram and 18.5 msec with 60 mg/d. The baseline QT interval in the study volunteers was not included in the FDA announcements, nor did it specify whether any developed a QT interval outside the normal range. The upper limit of normal ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Citalopram (Celexa) and QT Interval Prolongation
Article code: 1398b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian